Calendario›NERV›Roluperidone 64 mg
Roluperidone 64 mg
Ensayo de Minerva Neurosciences, Inc. en Negative Symptoms in Schizophrenia (del registro, en inglés).
Todo sobre el fármaco: Roluperidone.
- Fase
- Fase 1
- Estado
- Completado
- Participantes
- 17
- Centros
- 3
- Fin del objetivo primario
- ene 2024
Título oficial en el registro (en inglés): A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia
Qué significa cada fase y cada estado.
Estudio de intervención, no aleatorizado, abierto. Comenzó en oct 2023.
De principio a fin
- Empieza el ensayo (oct 2023)
- Lectura de resultados ene 2024 (real)
- Hoy
Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.
Qué mide
Extrapyramidal Symptoms Assessed by Abnormal Involuntary Movement Scale (AIMS) - Change From Baseline in AIMS Component Movement (Overall - Change from Baseline to End of Study (Day 17)) (del registro, en inglés)
Qué se prueba
Se evaluará la seguridad, la tolerancia, la farmacodinámica y la farmacocinética de la administración conjunta de Roluperidone y Olanzapine en adultos con síntomas negativos moderados a graves de esquizofrenia.
Lo que dice el documentoevaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of the Co-Administration of Roluperidone and Olanzapine in Adult Subjects with Moderate to Severe Negative Symptoms of Schizophrenia.
Traducción automática (claude-haiku-5-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.
Cómo lo describe el promotor
En el documentoEn inglés, del registroThe goal of this clinical trial is to evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of the Co-Administration of Roluperidone and Olanzapine in Adult Subjects with Moderate to Severe Negative Symptoms of Schizophrenia. The main question this clinical trial aims to answer are the pharmacodynamic and pharmacokinetic effects and safety of the concomitant therapy of Roluperidone with an established and widely used antipsychotic, such as olanzapine in order to provide further guidance to clinical practitioners that may prescribe off-label use of these drugs concomitantly in clinical practice. Eligible Participants will undergo the following study phases in the clinic: * Screening Phase: Between 2 and up to 28 days during which study eligibility will be established and subjects receiving psychotropics will be washed out. Subjects will remain inpatient at the clinical site at least through the end of Treatment Phase 2. * Treatment Phase 1: After the Baseline Visit, Roluperidone 64 mg/day will be administered as a monotherapy for 7 days (Days 1-7). * Treatment Phase 2: Concomitant administration of Olanzapine 10 mg/day and Roluperidone 64 mg/day for 10 days, starting on Day 8 (Days 8-17). Subjects may be discharged from the clinic at least 48 hours after the last administration of the study drugs and after the collection of the last plasma sample; however, the inpatient period may be extended at the discretion of the investigator. End of Study (EOS): Will take place at least 14 days after the last dose of the study.
Más ensayos de NERV
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Roluperidone | Fase 3 | Reclutando pacientes | dic 2027 (prevista) |
| Roluperidone 32 mg | Fase 3 | Completado | may 2020 (real) |
| MIN-117 5.0 mg | Fase 2 | Completado | nov 2019 (real) |
| MIN-101 | Fase 1 | Completado | jul 2017 (real) |
| MIN-101 | Fase 1 | Completado | abr 2017 (real) |
| MIN-101 | Fase 1 | Completado | feb 2015 (real) |
Todos los de NERV, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT06107803), actualizada en mar 2025.